More clarity around the reasons cancer medicines are rejected by the Pharmaceutical Benefits Advisory Committee (PBAC) would better inform discussions between clinicians and their patients, a medical oncologist says. Dr Deme Karikios, who practices at the Nepean Hospital and is a PhD candidate with the University of Sydney’s NHMRC Clinical Trials Centre, said inadequate cost-effectiveness ...
Reason for PBAC rejection of cancer medicines important for patients and doctors
By Mardi Chapman
31 Jan 2017